Cargando…

Safety and adverse reactions in subcutaneous allergen immunotherapy: a review

BACKGROUND AND AIM: Allergen immunotherapy (AIT) is the only treatment which acts on the causes of allergic diseases by modifying their natural history. In the eighties subcutaneous immunotherapy (SCIT) with high bio-logical power allergen extracts caused a number of severe systemic reactions and al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Incorvaia, Cristoforo, Cavaliere, Carlo, Schroeder, Jan W., Leo, Gualtiero, Nicoletta, Francesca, Barone, Alessandro, Ridolo, Erminia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mattioli 1885 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440773/ https://www.ncbi.nlm.nih.gov/pubmed/37539607 http://dx.doi.org/10.23750/abm.v94i4.14239

Ejemplares similares

The Present and Future of Allergen Immunotherapy in Personalized Medicine
por: Ridolo, Erminia, et al.
Publicado: (2022)

Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence
por: Martignago, Irene, et al.
Publicado: (2017)

Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

Patient’s compliance with allergen immunotherapy
por: Incorvaia, Cristoforo, et al.
Publicado: (2008)

Personalized medicine and allergen immunotherapy: the beginning of a new era?
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

How to fit allergen immunotherapy in the elderly
por: Ridolo, Erminia, et al.
Publicado: (2017)

Allergists and COVID-vaccine: which is the actual risk of reactions in allergic patients?
por: Pucciarini, Francesco, et al.
Publicado: (2022)

Can the Pattern of Early Sensitization to Allergen Molecules Drive a New Approach for Prevention of Allergy?
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

Two decades with omalizumab: what we still have to learn
por: Incorvaia, Cristoforo, et al.
Publicado: (2018)

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis
por: Lombardi, Carlo, et al.
Publicado: (2017)

Causes of Non-Adherence to Allergen-Specific Immunotherapy: A Foundation towards a Patient-Personalized Approach
por: Ridolo, Erminia, et al.
Publicado: (2023)

Importance of hypersensitivity in adverse reactions to drugs in the elderly
por: Ventura, Maria Teresa, et al.
Publicado: (2018)

Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?
por: Incorvaia, Cristoforo, et al.
Publicado: (2022)

Lipid transfer protein syndrome: How to save a life through careful education
por: Ridolo, Erminia, et al.
Publicado: (2022)

Characteristics of candidates for allergen immunotherapy
por: Ciprandi, Giorgio, et al.
Publicado: (2013)

Will Research on COVID-19 Stimulate the Identification of Immunological Mechanisms Underlying Some Protective Effects?
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

One more step towards a deeper understanding of the mechanisms of allergen immunotherapy
por: Incorvaia, Cristoforo
Publicado: (2018)

Dermatological manifestations during COVID-19 infection: a case series and discussion on the problem of differential diagnosis
por: Ridolo, Erminia, et al.
Publicado: (2021)

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

About the effect of pulmonary rehabilitation on lung function in patients with chronic obstructive pulmonary disease
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Assessing the Risk Factors for Refractory Eosinophilic Esophagitis in Children and Adults
por: Ridolo, Erminia, et al.
Publicado: (2019)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019)

IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

The quest for improving general and in hospital health care during COVID-19 pandemic
por: Ridolo, Erminia, et al.
Publicado: (2021)

New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
por: Frati, Franco, et al.
Publicado: (2014)

What still prevents to acknowledge a major role for pulmonary rehabilitation in COPD treatment?
por: Incorvaia, Cristoforo, et al.
Publicado: (2019)

Allergen specificity is relevant for immunotherapy prescription in polysensitised children
por: Ciprandi, Giorgio, et al.
Publicado: (2012)

Efficacy and Safety of Subcutaneous Allergen Immunotherapy for Allergic Rhinitis
por: Sohn, Myung Hyun
Publicado: (2018)

Bilastine: new insight into antihistamine treatment
por: Ridolo, Erminia, et al.
Publicado: (2015)

Local allergic rhinitis: evolution of concepts
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy
por: Frati, Franco, et al.
Publicado: (2012)

Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
por: Ridolo, Erminia, et al.
Publicado: (2013)

Retrospective evaluation of adverse reactions after subcutaneous allergen-specific immunotherapy in children with house dust mite allergy
por: Altas, Ugur, et al.
Publicado: (2023)

Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study
por: Savi, Eleonora, et al.
Publicado: (2017)

Current treatment strategies for seasonal allergic rhinitis: where are we heading?
por: Ridolo, Erminia, et al.
Publicado: (2022)

Patient's Adherence and Compliance and Quality of Life During/After VIT
por: Incorvaia, Cristoforo, et al.
Publicado: (2022)

Could a bite trigger the onset of cat allergy?
por: Leo, Gualtiero, et al.
Publicado: (2022)

Safety, Efficacy, and Preventive Role of Subcutaneous and Sublingual Allergen Immunotherapy for the Treatment of Pediatric Asthma
por: Giannetti, Arianna, et al.
Publicado: (2020)

Omalizumab, an anti-immunoglobulin E antibody: state of the art
por: Incorvaia, Cristoforo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bf16mcqsrgdead6d59f6l26t3v